Literature DB >> 27084375

Drug Formulation Advances in Extended-Release Medications for Pain Control.

Mark R Jones1, Martin J Carney1, Rachel J Kaye2, Amit Prabhakar3, Alan D Kaye4.   

Abstract

Prescription opioid abusers frequently tamper with opioid tablets in order to either accelerate the delivery of the euphoria-inducing agent or to alter the route of delivery, such that it may be delivered intranasally or intravenously. As one strategy to combat the opioid epidemic in the USA, drug manufacturers have begun to explore formulations which resist such tampering by abusers. Techniques to prevent tampering consist of physical barriers to crushing, chewing, and drug extraction, or aversive or antagonistic agents, incorporated within the formulation itself. Recent years have seen the development of numerous extended-release opioid agents, which are described in this review. This article provides a comprehensive summary of the pharmacology, benefits, risks, and processes behind the development of currently available extended-release opioid drugs, as well as a glimpse into promising future formulations.

Entities:  

Keywords:  Abuse; Extended-release formulation; Hydrocodone; Opioids; Oxycodone; Pain; Tamper resistance

Mesh:

Substances:

Year:  2016        PMID: 27084375     DOI: 10.1007/s11916-016-0565-9

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  68 in total

1.  12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.

Authors:  Warren Wen; Louise Taber; Shau Yu Lynch; Ellie He; Steven Ripa
Journal:  J Opioid Manag       Date:  2015 Jul-Aug

2.  Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.

Authors:  Stephen F Butler; Ryan Black; Jill M Grimes Serrano; Lesley Folensbee; Alan Chang; Nathaniel Katz
Journal:  Pain Med       Date:  2009-11-25       Impact factor: 3.750

3.  American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.

Authors:  Laxmaiah Manchikanti; Salahadin Abdi; Sairam Atluri; Carl C Balog; Ramsin M Benyamin; Mark V Boswell; Keith R Brown; Brian M Bruel; David A Bryce; Patricia A Burks; Allen W Burton; Aaron K Calodney; David L Caraway; Kimberly A Cash; Paul J Christo; Kim S Damron; Sukdeb Datta; Timothy R Deer; Sudhir Diwan; Ike Eriator; Frank J E Falco; Bert Fellows; Stephanie Geffert; Christopher G Gharibo; Scott E Glaser; Jay S Grider; Haroon Hameed; Mariam Hameed; Hans Hansen; Michael E Harned; Salim M Hayek; Standiford Helm; Joshua A Hirsch; Jeffrey W Janata; Alan D Kaye; Adam M Kaye; David S Kloth; Dhanalakshmi Koyyalagunta; Marion Lee; Yogesh Malla; Kavita N Manchikanti; Carla D McManus; Vidyasagar Pampati; Allan T Parr; Ramarao Pasupuleti; Vikram B Patel; Nalini Sehgal; Sanford M Silverman; Vijay Singh; Howard S Smith; Lee T Snook; Daneshvari R Solanki; Deborah H Tracy; Ricardo Vallejo; Bradley W Wargo
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

4.  Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.

Authors:  Ute Richarz; Sandra Waechter; Rainer Sabatowski; Leszek Szczepanski; Heinrich Binsfeld
Journal:  Pain Pract       Date:  2012-04-18       Impact factor: 3.183

5.  Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.

Authors:  Derry Ridgway; Maciej Sopata; Arvydas Burneckis; Lillian Jespersen; Christine Andersen
Journal:  J Pain Symptom Manage       Date:  2010-04       Impact factor: 3.612

6.  Recent developments toward the safer use of opioids, with a focus on hydrocodone.

Authors:  Jordan R Covvey
Journal:  Res Social Adm Pharm       Date:  2015-02-13

7.  Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules.

Authors:  Murad R Melhem; Christopher M Rubino; Stephen J Farr; Cynthia Y Robinson
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

8.  Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain.

Authors:  Joris Vandenbossche; Ute Richarz; Henry M Richards
Journal:  J Pain Res       Date:  2012-11-09       Impact factor: 3.133

9.  Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study.

Authors:  Seong Hoon Shin; Ho Sup Lee; Yang Soo Kim; Young Jin Choi; Sung Hyun Kim; Hyuk Chan Kwon; Sung Yong Oh; Jung Hun Kang; Chang Hak Sohn; Sang Min Lee; Jin Ho Baek; Young Joo Min; Choongrak Kim; Joo Seop Chung
Journal:  Cancer Res Treat       Date:  2014-07-21       Impact factor: 4.679

10.  Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.

Authors:  Emily C McNaughton; Paul M Coplan; Ryan A Black; Sarah E Weber; Howard D Chilcoat; Stephen F Butler
Journal:  J Med Internet Res       Date:  2014-05-02       Impact factor: 5.428

View more
  3 in total

Review 1.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

Review 2.  America's Opioid Epidemic: a Comprehensive Review and Look into the Rising Crisis.

Authors:  Peter S Ostling; Kelly S Davidson; Best O Anyama; Erik M Helander; Melville Q Wyche; Alan D Kaye
Journal:  Curr Pain Headache Rep       Date:  2018-04-04

Review 3.  A Brief History of the Opioid Epidemic and Strategies for Pain Medicine.

Authors:  Mark R Jones; Omar Viswanath; Jacquelin Peck; Alan D Kaye; Jatinder S Gill; Thomas T Simopoulos
Journal:  Pain Ther       Date:  2018-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.